NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: HEXAGON · data 2026-11-01
Hexagon Nutrition Limited
In plain words
Price: 30.8% below its 52-week high of ₹78.25.
Delivery: 56.5% of traded shares were kept for delivery over the last 10 sessions, against 47.9% over the last 21.
Latest results: a net profit of ₹8 cr for the quarter ended Jun 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | — |
| Net profit (last 12 months) | — |
| Sales growth, 3 years (yearly) | 11.1% |
| Profit growth, 3 years (yearly) | 88.0% |
At a glance
Promoters 64.4%, pledged 0.0%, institutions 4.4%.
ROE 17.7%, ROCE 18.7%: how much profit it earns on the money it uses.
Debt/equity 0.14, Profit growth 88.0% and sales growth 11.1% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Profit grew 88.0% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
HEXAGON Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹104.31 crore, down 9.3% QoQ.
Net profit was ₹8.07 crore, down 26% QoQ.
Operating margin was 11.3%.
EPS was ₹0.67, down 32.3% QoQ.
HEXAGON के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹104.31 करोड़; पिछली तिमाही की तुलना में 9.3% की गिरावट।
शुद्ध मुनाफ़ा: ₹8.07 करोड़; पिछली तिमाही की तुलना में 26% की गिरावट।
ऑपरेटिंग मार्जिन: 11.3%।
EPS: ₹0.67; पिछली तिमाही की तुलना में 32.3% की गिरावट।
HEXAGONના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹104.31 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 9.3% ઘટાડો.
ચોખ્ખો નફો: ₹8.07 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 26% ઘટાડો.
ઓપરેટિંગ માર્જિન: 11.3%.
EPS: ₹0.67; ગયા ક્વાર્ટરની સરખામણીએ 32.3% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
14/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: Net −₹4.61 cr in bulk/block deals over 90 days (0 net buying days, 1 net selling day): more sold than bought.
- Insider / SAST buys 9/15: 0 insider buy days (promoter group among them) and 2 SAST acquisition days in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Insider ● Deal ● Dividend ● Results
- 28 Sept 26Insider SAST disclosure: Dr. Nikhil Kelkar +4 acquired 40,000 shares +0.4% next session
- 16 Sept 26Deal Bulk deal: CP CAPITAL LIMITED sold ₹4.61 cr -0.4% next session
- 15 Sept 26Dividend Dividend ₹0.3 (ex-date) -5.9% next session
- 21 Aug 26Insider SAST disclosure: Mr. Vikram Kelkar +3 acquired 64,000 shares +0.5% next session
- 12 Aug 26Results Q1 FY27 results: net profit ₹8.1 cr +0.9% next session
- 30 Jul 26Results Q4 FY26 results: net profit ₹10.9 cr +3.4% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹104 cr | ₹8 cr | — | 11.3% | 0.67 |
| Mar 2026 | ₹115 cr | ₹11 cr | — | 13.1% | 0.99 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 |
|---|---|---|
| Promoters | 64.36% | 64.29% |
| Foreign institutions (FII) | 0.29% | 0.29% |
| Domestic institutions (DII) | 4.12% | 6.43% |
| Mutual funds | 2.01% | 2.44% |
| Retail investors | 17.39% | 15.41% |
| Number of shareholders | 21,792 | 20,187 |
Common questions
What was Hexagon Nutrition Limited's latest quarterly profit?
Hexagon Nutrition Limited reported a net profit of ₹8 cr for the quarter ended Jun 2026, on revenue of ₹104 cr.
How much do promoters hold in Hexagon Nutrition Limited?
Promoters held 64.36% of Hexagon Nutrition Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Hexagon Nutrition Limited debt-free?
Its latest reported debt-to-equity ratio is 0.14.
What is the 52-week high and low of Hexagon Nutrition Limited?
The 52-week high is ₹78.25 and the 52-week low is ₹48.1.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Hexagon Nutrition Limited | ₹54.11 | ₹664 cr | — | — | 17.7% | 18.7% | 0.14 | +12.1% |
| Shree Ganesh Remedies Ltd. | ₹617.25 | ₹792 cr | 51.3 | — | 11.5% | 14.4% | 0.19 | +24.7% |
| Kilitch Drugs (India) Limited | ₹201.32 | ₹703 cr | 23 | — | 12.5% | 12.3% | 0.32 | +1.5% |
| Valiant Laboratories Ltd. | ₹128.4 | ₹695 cr | 43.5 | — | -1.2% | 0.2% | 0.15 | +48.6% |
| Wanbury Limited | ₹189.21 | ₹664 cr | 11.6 | — | 64.9% | 31.1% | 1.57 | -25.8% |
| Amanta Healthcare Limited | ₹163.56 | ₹632 cr | 43.3 | — | 9.4% | 11.5% | 1.11 | +33.5% |
Compare HEXAGON with SGRL in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open HEXAGON in NSE Scanner →